CLDX has been granted a new patent
Dec 25, 2024, 11:32 PM
-2.87%
What does CLDX do
Celldex Therapeutics, based in Hampton, New Jersey, develops novel therapeutics targeting mast cell-mediated diseases and employs 160 staff. Their pipeline includes Barzolvolimab and the bispecific antibody CDX-585 for inflammatory diseases and oncology.
CLDX filed a patent for "anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs" on Wed, March 15, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
